Page last updated: 2024-09-04

lonafarnib and navitoclax

lonafarnib has been researched along with navitoclax in 1 studies

Compound Research Comparison

Studies
(lonafarnib)
Trials
(lonafarnib)
Recent Studies (post-2010)
(lonafarnib)
Studies
(navitoclax)
Trials
(navitoclax)
Recent Studies (post-2010) (navitoclax)
224349042915401

Protein Interaction Comparison

ProteinTaxonomylonafarnib (IC50)navitoclax (IC50)
Bcl-2-like protein 11Homo sapiens (human)0.0043
Apoptosis regulator Bcl-2Homo sapiens (human)0.0091
Bcl-2-like protein 1Homo sapiens (human)0.0168
Aspartyl/asparaginyl beta-hydroxylaseHomo sapiens (human)1.0925
Bcl-2-like protein 2Homo sapiens (human)0.07

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Bonovolias, ID; Chatzopoulou, M; Demopoulos, VJ; Nicolaou, I; Tsiftsoglou, AS; Vizirianakis, IS1

Reviews

1 review(s) available for lonafarnib and navitoclax

ArticleYear
Toward the development of innovative bifunctional agents to induce differentiation and to promote apoptosis in leukemia: clinical candidates and perspectives.
    Journal of medicinal chemistry, 2010, Oct-14, Volume: 53, Issue:19

    Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Differentiation; Clinical Trials as Topic; Drug Evaluation, Preclinical; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Humans; Leukemia; Multipotent Stem Cells; Neoplastic Stem Cells; Pharmacogenetics

2010